Welcome to our dedicated page for Quince Therapeutics SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quince Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quince Therapeutics's regulatory disclosures and financial reporting.
Quince Therapeutics director June Bray received a new stock option grant. On 01/02/2026, Bray was granted director stock options covering 18,724 common shares at an exercise price of $3 per share, with no cash paid for the options themselves.
The options vest in equal quarterly installments over a one-year period, meaning the grant is tied to ongoing board service during 2026. Bray elected to receive this option award in lieu of the annual director cash retainer for 2026 under Quince Therapeutics' Outside Director Compensation Policy. Following this grant, Bray beneficially owns 18,724 derivative securities directly.
Quince Therapeutics, Inc. insider Dirk Thye, who serves as director and as CEO and CMO, reported a transfer of common shares dated 12/10/2025.
The reported transaction with code G involved 739,885 common shares at a stated price of $0, moving from direct to indirect beneficial ownership through the Thye Trust. After this transaction, Thye held 255,000 common shares directly and 739,885 common shares indirectly via the Thye Trust.
Quince Therapeutics reported third‑quarter results and disclosed “substantial doubt” about its ability to continue as a going concern. The company posted a Q3 net loss of $13.4 million and a nine‑month net loss of $44.5 million.
Cash, cash equivalents, and short‑term investments were $26.3 million as of September 30, 2025. Quince raised additional capital through an ATM program (net $4.3 million YTD) and a June 2025 private placement that issued common stock, pre‑funded warrants, and common warrants for gross proceeds of $11.5 million.
The balance sheet shows a $17.5 million current portion of the EIB loan (fair value) due August 2026, $61.2 million in long‑term contingent consideration tied to the EryDel acquisition, and $14.9 million warrant liabilities. Stockholders’ equity was $1.1 million. Shares outstanding were 55,681,490 as of November 6, 2025.
Quince Therapeutics, Inc. filed a current report to note that it has announced its financial results for the quarter ended September 30, 2025 and shared recent business highlights. The company states that these details are contained in a press release dated November 12, 2025, which is furnished as Exhibit 99.1 to this report rather than being fully included in the body of the document.
Quince Therapeutics (QNCX) filed an 8-K under Regulation FD to correct an Investor Day statement. The company removed Slide 57 and the related video from its October 2, 2025 Virtual Investor Day and advised investors not to rely on the slide’s claim that IntraBio’s N-acetyl-L-leucine (NALL) “failed Phase 2 A-T study across all endpoints.”
Quince clarified its statement drew from a European Journal of Paediatric Neurology article describing a single-site study in ataxia-telangiectasia, which reported no significant improvements in ataxia symptoms or motor function, and was not the multi-site IntraBio Phase 2 Study.
Quince Therapeutics (QNCX) filed a prospectus supplement for an at‑the‑market offering of up to $75,000,000 of common stock under its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC.
As of this supplement, the company has sold 4,823,859 shares for $6,496,274 in gross proceeds, leaving $68,503,726 available for future sales under the program. The company states it is currently no longer subject to the offering limits of General Instruction I.B.6. of Form S-3; if it becomes subject again, it will file another supplement.
QNCX common stock trades on Nasdaq under “QNCX.” The closing price was $1.93 on October 16, 2025.
Quince Therapeutics, Inc. reports an amendment to its unsecured credit facility with the European Investment Bank. For the period from January 1, 2026 to March 31, 2026, the company’s required minimum cash balance under the EIB Facility will be reduced from EUR 14,650,000 to EUR 5,000,000, temporarily easing its cash covenant. During this same period, out of the overall 9% Deferred Interest Rate on Tranche A and Tranche B, 1% will be converted into a Fixed Rate to be paid on March 31, 2026 on those tranches. The full amendment will be filed as an exhibit to the company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.
Quince Therapeutics, Inc. Schedule 13G filed by Nantahala Capital Management, LLC and two individuals reports collective beneficial ownership of 4,765,862 shares, representing 9.99% of outstanding common stock as of June 30, 2025. The reported holdings include 2,237,562 shares that the reporting persons may acquire within 60 days through the exercise of warrants. Nantahala and principals Wilmot B. Harkey and Daniel Mack report no sole voting or dispositive power but share voting and dispositive power over all reported shares. Blackwell Partners LLC - Series A, a fund advised by Nantahala, is identified as having rights to dividends or sale proceeds on more than 5% of the shares reported.
Quince Therapeutics is a late-stage biotech developing the AIDE red blood cell encapsulation platform and a Phase 3 lead asset, eDSP, targeting Ataxia-Telangiectasia. The company reported consolidated assets of $117.2 million, liabilities of $105.5 million, and stockholders' equity of $11.7 million as of June 30, 2025. Cash, cash equivalents and short-term investments totaled $34.7 million, while the accumulated deficit was $407.6 million.
Operating results show a continuing loss: $16.0 million net loss for the quarter and $31.1 million for the six months ended June 30, 2025, driven by higher R&D spending ($14.7 million for six months) and other non-cash fair value adjustments. The balance sheet includes €10.0 million ($11.7M) outstanding on an EIB loan, contingent consideration of $59.1 million, and warrant liabilities of $15.1 million. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern within one year and notes the need for additional financing despite recent capital raises totaling approximately $14.4 million from a June 2025 private placement and ATM activity.
Quince Therapeutics, Inc. reported that on August 11, 2025 it announced its financial results for the quarter ended June 30, 2025 and provided recent business highlights. The company states the related press release is furnished as Exhibit 99.1 to this Current Report. The filing explicitly says the information (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. No financial figures or business-detail text from the press release are included in the provided document. The report is signed by Dirk Thye, Chief Executive Officer and Chief Medical Officer.